A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
-
Society
Taiwan headline news
03/30/2026 09:40 AM -
Business
Taiwan shares open lower
03/30/2026 09:07 AM -
Politics
TPP rally against Ko Wen-je verdict draws thousands in Taipei
03/29/2026 09:49 PM -
Business
Sun PhuQuoc Airways launches Taipei-Phu Quoc flights
03/29/2026 08:27 PM -
Politics
Taiwan's new ambassador arrives in Belize
03/29/2026 06:43 PM